Skip to main content
16/05/2023

La Sonrisa de Daniela dona 32.485 € for research on Langerhans cell histiocytosis at Vall d'Hebron

Entrega del donatiu de La Sonrisa de Daniela al VHIR

Entrega del donatiu de La Sonrisa de Daniela al grup de Càncer i Malalties Hematològiques Infantils del VHIR.

16/05/2023

Gràcies al donatiu, el grup de Càncer i Malalties Hematològiques Infantils del VHIR investiga per explorar l’ús de la biòpsia líquida per a la predicció de l’evolució dels pacients amb aquesta malaltia minoritària.

Langerhans cell histiocytosis is a neoplasm that affects 1 in 200,000 children, produced by the proliferation and dysregulation of dendritic cells, a type of immune system cells. To investigate this disease, the association La Sonrisa de Daniela has donated 32.485 € to the group of Childhood Cancer and Blood Disorders of the Vall d'Hebron Research Institute (VHIR).

Langerhans cell histiocytosis can cause a wide spectrum of clinical manifestations, which can range from relatively benign bone lesions to more serious conditions. A significant percentage of patients do not respond to initial treatment or relapse, most of them within the first two years after diagnosis.

There is currently no consensus on the most appropriate treatment or the optimal time to initiate it. The project led by Dr. Josep Roma, principal investigator of the Childhood Cancer and Blood Disorders group at VHIR, will investigate the use of liquid biopsy (obtained from blood or cerebrospinal fluid) to improve the prediction of the evolution of patients. "The potential of liquid biopsy in the follow-up of histiocytosis is enormous, and its clinical potential is only beginning to emerge. However, comprehensive clinical implementation will not be possible without the completion of validation studies such as those proposed in this project", states Dr. Roma.

La Sonrisa de Daniela

La Sonrisa de Daniela is a non-profit association created by the parents of Daniela, a 7-year-old girl who in December 2016 was diagnosed with Langerhans cell histiocytosis. Its objective is to organize multiple activities (for children, sports, leisure, etc) to obtain resources that go entirely to the research line in Langerhans cell histiocytosis of VHIR, with which they have been collaborating since 2019.

Related news

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Vall d'Hebron presents positive results from two studies in transfusion-dependent thalassaemia and severe bone marrow aplasia at the EBMT Annual Meeting on haematopoietic stem cell transplantation.

Related professionals

Josep Roma  Castanyer

Josep Roma Castanyer

Main researcher
Childhood Cancer and Blood Disorders
Read more
Maria Isabel  Benitez  Carabante

Maria Isabel Benitez Carabante

Childhood Cancer and Blood Disorders
Read more
Raquel Hladun Alvaro

Raquel Hladun Alvaro

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more
Maria Eugenia Bustelo Almeida

Maria Eugenia Bustelo Almeida

Research technician
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.